Date
Time
Dr. Singleton, speaking on behalf of HEMA Biologics, will discuss a treatment option for patients 12 years of age or older with hemophilia A or B with inhibitors. Sponsored by HEMA Biologics.
Speakers: Tammuella “Tami” Chrisentery-Singleton, MD
About the Speakers:
Tammuella “Tami” Chrisentery-Singleton, MD
As the Chief Science Officer (CSO) for ATHN, Dr. Tami Chrisentery-Singleton works at the strategic and policy level to inform the scientific direction of ATHN. She works across the organization to define, develop, and implement ATHN’s science and research capabilities as well as to ensure ATHN’s commitment to public health. Additionally, she cares for adult and pediatric hematology patients at the Ochsner Center for Hemostasis and Thrombosis.
Dr. Singleton's areas of special interest include sickle cell disease, rare blood disorders, gene therapy, and musculoskeletal ultrasound in hemophilia patients. She has authored numerous publications and led more than 60 clinical trials and research studies. Before joining ATHN, Dr. Singleton was the Chief of Pediatric Hematology and Director of the Hemophilia Treatment Center for the Louisiana Center for Advanced Medicine. She also previously served as the Chief of Pediatric Hematology and Oncology, the Director of the Sickle Cell Center of South Louisiana, and the Associate Director of the Louisiana Center for Bleeding and Clotting Disorders at the Tulane University School of Medicine/Tulane Hospital for Children.